Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|April 19, 2023
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trialTycel Phillips, Kristen Migliaccio-Walle, Kristina S Yu, et al.
Blood Reviews|July 19, 2022
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomasFranck Morschhauser, Gilles Salles, Connie Lee Batlevi, et al.
Blood Advances|January 11, 2023
Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activityKang Le, Jing Sun, Javid Ghaemmaghami, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2013
Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient managementOana Paun, Tycel Phillips, Pingfu Fu, et al.
The Oncologist|March 27, 2023
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and ChemotherapyJohn M Burke, Nicholas Liu, Kristina S Yu, et al.
Haematologica|September 5, 2024
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trialTycel Phillips, Michael Wang, Tadeusz Robak, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 27, 2023
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With EpcoritamabTycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, et al.
Blood Advances|May 23, 2024
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysisMichael Wang, Tadeusz Robak, Kami J Maddocks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2021
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT ActivationNan Hu, Fangyang Wang, Tianyu Sun, et al.
American Journal of Hematology|August 27, 2017
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomasPhilip S Boonstra, Avery Polk, Noah Brown, et al.
Pageof 6